<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542514</url>
  </required_header>
  <id_info>
    <org_study_id>iLOC</org_study_id>
    <nct_id>NCT02542514</nct_id>
  </id_info>
  <brief_title>Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma</brief_title>
  <acronym>iLOC</acronym>
  <official_title>Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open label, prospective, multicenter, phase II study which aims to define&#xD;
      ibrutinib efficacy in patients with relapsed or refractory primary central nervous lymphoma&#xD;
      (PCNSL) or intraocular lymphoma (IOL) as measured by the disease control (DC) rate (complete&#xD;
      response (CR) + uncertain complete response (Ru) + partial response (PR) stabilized disease&#xD;
      (SD)) after 2 cycles of treatment according to International study group for PCNSL (IPCG)&#xD;
      criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate (CR + CRu + PR +SD)</measure>
    <time_frame>2 months</time_frame>
    <description>Disease control (DC) rate (CR + CRu + PR + SD) after 2 cycles of treatment according to IPCG criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AE</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate tolerance and toxicity of ibrutinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control</measure>
    <time_frame>4, 6, 9 and 12 months</time_frame>
    <description>according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response (OR)</measure>
    <time_frame>4, 6, 9 and 12 months</time_frame>
    <description>according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response (CR) rate</measure>
    <time_frame>4, 6, 9 and 12 months</time_frame>
    <description>according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>4, 6, 9 and 12 months</time_frame>
    <description>according to IPCG criteria evaluated locally by investigators and the results of the MRI review (maximum of 6 MRI review per patient).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>concentration of ibrutinib in cerebrospinal fluid</measure>
    <time_frame>baseline and 2 months</time_frame>
    <description>Pharmacokinetics of ibritunib in the cerebrospinal fluid.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Primary Central Nervous Lymphoma</condition>
  <condition>Intraocular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibrutinib in monotherapy 28 days/cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)</description>
    <arm_group_label>Ibrutinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of PCNSL or cytologically proven diagnosis of IOL&#xD;
             or lymphomatous meningitis of B-cell type. In case of CNS lymphoma relapse or&#xD;
             refractory PCNSL, cerebral biopsies are not required if imaging reveals typical images&#xD;
             of PCNSL. In case of isolated IOL relapse, vitrectomy is not required if i) vitrectomy&#xD;
             was part of the initial diagnosis workout, and ii) ocular examination and dosage of&#xD;
             IL-10 in the anterior chamber of the eye performed at relapse or progression are&#xD;
             highly in favour of IOL relapse (&gt; 50 pg/ml in aqueous humor or 400 pg/ml in&#xD;
             vitreous).&#xD;
&#xD;
          2. Aged 18 years and older.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.&#xD;
&#xD;
          4. Life expectancy ≥ 3 months.&#xD;
&#xD;
          5. No more than 4 lines of anti-cancer treatment received.&#xD;
&#xD;
          6. Patients must have recovered within 28 days to a grade ≤ 1 from all toxicities related&#xD;
             to prior treatments.&#xD;
&#xD;
          7. Adequate Laboratory Parameters within 14 days:&#xD;
&#xD;
          8. Measurable PCNSL as diagnosed on MRI&#xD;
&#xD;
          9. Highly effective method of birth control during and after the study consistent. Men&#xD;
             must agree to not donate sperm during and after the study. These restrictions apply&#xD;
             for 1 year after the last dose of study drug.&#xD;
&#xD;
         10. Women of childbearing potential must have a negative serum beta-hCG or urine pregnancy&#xD;
             test at Screening.&#xD;
&#xD;
         11. Sign of an informed consent document.The informed consent document can be signed by a&#xD;
             person of confidence in case neurologic disorders related to the disease prevent the&#xD;
             patient to sign himself.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to any excipients of the drug.&#xD;
&#xD;
          2. T-cell lymphoma.&#xD;
&#xD;
          3. Prior history of malignancies other than lymphoma (except for basal cell or squamous&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix or breast), prior&#xD;
             history of systemic lymphoma, unless the patient has been free of the disease for ≥ 3&#xD;
             years.&#xD;
&#xD;
          4. Prior history of organ transplantation or other cause of severe immunodeficiency.&#xD;
&#xD;
          5. Major surgery, within 4 weeks prior to the first dose of study drug.&#xD;
&#xD;
          6. History of stroke or intracranial hemorrhage within 6 months prior to randomization.&#xD;
             Patients with post-biopsies hemorrhagic sequela defined as a small hyperdense lesion &lt;&#xD;
             3 mm on T2* sequence won't be excluded.&#xD;
&#xD;
          7. Requires anticoagulation with warfarin or equivalent vitamin K antagonists or ongoing&#xD;
             warfarin medication or other equivalent vitamin K antagonists.&#xD;
&#xD;
          8. Any anti-platelet aggregant medication except acetyl salicylic acid ≤ 75 mg/day.&#xD;
&#xD;
          9. Requires treatment with strong CYP3A4 inhibitors.&#xD;
&#xD;
         10. Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             Screening, or any Class 3 or Class 4 cardiac disease as defined by the New York Heart&#xD;
             Association Functional Classification.&#xD;
&#xD;
         11. Vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of&#xD;
             study drug.&#xD;
&#xD;
         12. Known history of HIV or active Hepatitis C Virus (HCV; RNA polymerase chain reaction&#xD;
             [PCR]-positive) or active Hepatitis B Virus (HBs Ag positive or DNA PCR-positive)&#xD;
             infection or any uncontrolled active systemic infection requiring intravenous (IV)&#xD;
             antibiotics.&#xD;
&#xD;
         13. Any life-threatening illness, medical condition, or organ system dysfunction which&#xD;
             could compromise the subject's safety, interfere with the absorption or metabolism of&#xD;
             ibrutinib capsules, or put the study outcomes at undue risk.&#xD;
&#xD;
         14. Inability to swallow capsules.&#xD;
&#xD;
         15. Pregnancy or lactation.&#xD;
&#xD;
         16. Use of anti-cancer drug therapy within 21 days prior to the first dose of study drug.&#xD;
&#xD;
         17. Previous treatment by BTK inhibitors and PI3K inhibitors.&#xD;
&#xD;
         18. Known bleeding diathesis.&#xD;
&#xD;
         19. Inclusion in another experimental anti-cancer drug therapy*.&#xD;
&#xD;
         20. Assessed by the investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         21. Patient under measure of legal protection.&#xD;
&#xD;
         22. No social security affiliation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole Soussain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU d'ESTAING</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCNSL</keyword>
  <keyword>IOL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Intraocular Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

